Global pharmaceutical giant Lupin Limited (Lupin) is taking a big step to increase its market share in China's healthcare industry by signing a license and supply agreement for the commercialization of Tiotropium Dry Powder Inhaler (DPI) with Sino Universal Pharmaceuticals (SUP).
The goal of this strategic partnership is to treat chronic obstructive pulmonary disease (COPD) in China, a market that is experiencing an increasing demand for cutting-edge respiratory care products.
Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was followed in making the disclosure.
As per the agreement, SUP will be in charge of securing the required regulatory clearances in order to market Tiotropium DPI in China.
Lupin will continue to be in charge of the product's manufacturing and maintain its position as the holder of the marketing license.
Lupin is taking a calculated move with this cooperation to enter the rapidly expanding Chinese pharmaceutical industry, especially in the respiratory sector. A well-known drug that is effective in boosting lung function and increasing the quality of life for those with respiratory disorders like COPD is tiotropium DPI.
The deal makes use of both businesses' advantages: SUP's local market knowledge and skills in negotiating the regulatory environment and launching products in China, and Lupin's experience in pharmaceutical production and possessing marketing authorizations.
Lupin will be able to greatly increase its presence in China thanks to the partnership. Lupin seeks to address the rising incidence of respiratory disorders in the area by guaranteeing that patients have prompt access to cutting-edge, superior healthcare solutions. This action is in line with Lupin's overarching plan to bolster its respiratory health portfolio globally.
Due to its enormous population, growing healthcare awareness, and rising rates of chronic diseases like COPD, the Chinese market offers pharmaceutical companies a significant opportunity. The DPI's active component, tiotropium, is a long-acting anticholinergic bronchodilator that facilitates breathing by widening the lungs' airways. Patients can administer it in a convenient and efficient way with the use of a dry powder inhaler.
Also Read: A Lot of Weightlifting Awaits Lip-Bu Tan, But is Intel Ready for Him?
This deal demonstrates Lupin's dedication to creating and supplying essential medications for respiratory conditions. Successful market penetration and commercialization depend on collaborating with a local organization like SUP, which has a robust distribution network and knowledge of the Chinese pharmaceutical ecosystem. With more than 18 years of experience in China providing pharmaceutical distribution and administration services, SUP is in a strong position to spearhead Tiotropium DPI's regulatory approval and subsequent market launch.